文献
J-GLOBAL ID:201202266462458115
整理番号:12A1074872
韓国における転移性結腸直腸癌の一次治療としてのベバシズマブとFOLFIRIの併用療法対FOLFIRI単独療法の臨床効果と対費用効果
Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
著者 (14件):
LEE Eui-Kyung
(Sungkyunkwan Univ. School of Pharmacy, Seoul, KOR)
,
PARK Mee-Hye
(Sungkyunkwan Univ. School of Pharmacy, Seoul, KOR)
,
REVIL Cedric
(F. Hoffman-La Roche Ltd., Basel, CHE)
,
NGOH Charles A.
(F. Hoffman-La Roche Ltd., Basel, CHE)
,
LISTER Johanna
(Analytica International Inc, Loerrach, DEU)
,
KWON Jeong-Mi
(Sookmyung Women’s Univ., Seoul, KOR)
,
PARK Seok-Jin
(Sookmyung Women’s Univ., Seoul, KOR)
,
PARK Young-Suk
(Sungkyunkwan Univ. School of Medicine, Seoul, KOR)
,
SHIN Sang-Joon
(Yonsei Univ. Coll. of Medicine, Seoul, KOR)
,
LEE Myung-Ah
(Catholic Univ. Korea Coll. of Medicine, Seoul, KOR)
,
LEE Nam-Su
(Soonchunhyang Univ. Coll. of Medicine, Seoul, KOR)
,
ZANG Dae-Young
(Hallym Univ. Coll. of Medicine, Anyang, KOR)
,
BAE Eun-Jin
(Roche Korea Co, Ltd, Seoul, KOR)
,
KANG Mi-Jeong
(Roche Korea Co, Ltd, Seoul, KOR)
資料名:
Clinical Therapeutics
(Clinical Therapeutics)
巻:
34
号:
6
ページ:
1408-1419
発行年:
2012年06月
JST資料番号:
A1157A
ISSN:
0149-2918
資料種別:
逐次刊行物 (A)
発行国:
オランダ (NLD)
言語:
英語 (EN)